



15th International Meeting • Santa Barbara, California

Viral Vectors and Vaccines ***For Pandemic Viruses, Cancer Vaccines, and Gene Therapy***

SUNDAY, NOVEMBER 2, 2008

4:00-6:00 pm **Registration and Welcome Reception**

MONDAY, NOVEMBER 3, 2008

7:00-8:00 am **Registration, Breakfast - Meeting Room Foyer**

8:00-8:30 am **Introduction By Conference Chair**

Mark Plavsic, DVM, PhD - *Genzyme Corporation*

8:30-9:15 am **Clearance of Herpes Simplex Virus During Purification of rAAV2**

David McNeilly - *Genzyme Corporation*

9:15-10:00 am **From Bench to Clinic: Case Studies Describing Successes and Challenges in the Development of Recombinant AAV Clinical Gene Therapy**

Fraser Wright, PhD - *Children's Hospital of Philadelphia*

10:00-10:30 am **Break - Exhibit Area**

10:30-11:00 am **Technical Workshop - BIA Separations, Inc. (Anacapa Room)**

11:00-11:30 am **Technical Workshop - EMD Chemicals, Inc. (Anacapa Room)**

11:30 am-Noon **Technical Workshop - GE Healthcare (Anacapa Room)**

Noon-1:30 pm **Lunch - Exhibit Area**

1:00-1:30 pm **Poster Session - Exhibit Area**

1:30-2:15 pm **Comparability Studies for Gene Therapy Products: Expectations Following Manufacturing Changes During Early and Late Phase Investigations**

Denise Gavin, PhD - *FDA CBER*

2:15-3:00 pm **Intensification of a Recombinant Ad35 Manufacturing Process to Prepare for Commercial-Scale Production**

Emile van Corven, PhD - *CruceCell*

3:00-3:30 pm **Break - Exhibit Area**

3:30-4:15 pm **Potency Assays: What Are the Requirements and Why?**

Joyce Frey-Vasconcells, PhD - *PharmaNet, Inc.*

4:15-5:00 pm **Transitioning a Phase 1 Clinical rAAV1 Process to Later-Stage Manufacturing**

Barbara Thorne, PhD - *Targeted Genetics Corporation*

6:00-7:30 pm **Reception - Exhibit Area**



TUESDAY, NOVEMBER 4, 2008

- 7:30-8:30 am **American Breakfast - Exhibit Area**
- 8:30-9:15 am **Large-Scale Production and Purification of Recombinant Adeno-Associated Viral Vectors**
David Knop, PhD - *Applied Genetic Technologies Corporation*
- 9:15-10:00 am **Biosafety Testing of Cell Lines Used in Virus Vector and Vaccine Production**
Merribeth Morin, PhD - *MicroTest Laboratories*
- 10:00-10:30 am **Break - Exhibit Area**
- 10:30-11:15 am **Examining Assumptions Underlying Virus Infectivity Assays - Effects on Titer Determination of the Adenovirus Reference Material**
Daniel Giroux - *Ventana Biosciences, Inc.*
- 11:15 am-Noon **Adenovirus Viral Vector Purification Process Development: Considerations in Moving from Phase II to Phase III**
Nicole Berard - *Genzyme Corporation*
- Noon-6:00 pm **Free Afternoon with Recommended Activities**

WEDNESDAY, NOVEMBER 5, 2008

- 7:30-8:30 am **Breakfast - Exhibit Area**
- 8:30-9:15 am **Current Developments in the Characterization of Poxvirus Vectors Using Novel Flow Cytometry-Based Assays**
Zengji Li, PhD, DSc - *BN ImmunoTherapeutics*
- 9:15-10:00 am **Preclinical Efficacy of a Plant-Produced Subunit HA-Based Vaccine Candidate**
Vidadi Yusibov, PhD - *Fraunhofer USA Center for Molecular Biotechnology*
- 10:00-10:30 am **Break - Exhibit Area**
- 10:30-11:00 am **Technical Workshop - Corning (Anacapa Room)**
- 11:00-11:30 am **Technical Workshop - SAFC Pharma (Anacapa Room)**
- 11:30 am-Noon **Technical Workshop - Pall Life Sciences (Anacapa Room)**
- Noon-1:30 pm **Lunch - Exhibit Area**
- 1:00-1:30 pm **Poster Session - Exhibit Area**
- 1:30-2:15 pm **Rapid Analysis of Adenoviruses with Novel Bio-Monolith Anion-Exchange HPLC Columns to Support the Development of a High-Titre Manufacturing Platform**
Roger Lias, PhD - *Eden Biodesign, Ltd.*
- 2:15-3:00 pm **Efficient Production of Gene Delivery Vectors by Large-Scale Transfection Technology**
Amine Kamen, PhD - *National Research Council Canada-Biotechnology Research Institute*
- 3:00-3:30 pm **Break - Exhibit Area**
- 3:30-4:15 pm **Development of a Manufacturing Upstream Process for the Production of Adenovirus Vectors**
Haodi Dong - *Genzyme Corporation*
- 4:15-5:00 pm **Lessons Learned from the Advexin MAA and BLA Filings: A CMC Perspective**
Joseph Senesac - *Introgen Therapeutics, Inc.*